Apollo Diagnostics LLC
Apollo will develop non-invasive signatures for early cancer detection and prediction of risk, progression and outcomes of proposed therapy.
- Stage Product In Development
- Industry Biotechnology
- Location Washington, D.C., DC, USA
- Currency USD
- Founded December 2011
- Employees 2
- Website apollodiagnostics.com
Company Summary
For cancer patients and pharmaceutical companies worldwide who annually spend over 10 billion dollars on biomarker discovery and diagnostics, Apollo’s multivariate non-invasive cancer signatures integrate all the metabolites, proteins and genetic factors that accurately predict clinical performance in diagnostics, as well as prognosis of disease progression, patient’s response to treatment options and the outcomes of the proposed therapy.
Team
-
Martin N. MartinovChief Technology Officer
Dr. Martinov has implemented extensive IT solutions in pharmaceuticals, diagnostics, and imaging. He holds an MS in Biotechnology from University of Sofia, Bulgaria, a PhD in Molecular Biophysics from Florida State University, Tallahassee, FL and has done post-doctoral research at Rensselaer Polytechnic Institute, Troy, NY.
-
Nikola K. KaludovScientific Operations
Dr. Kaludov is an experienced executive with extensive R&D expertise and a successful industry track record. As an industry executive has transformed two biotechnology research platforms into product pipelines, taken a product through pre-clinical development and IND, and founded one biotechnology company. Nick holds a PhD from Florida State University, a M.S. from University of Sofia and has done post-doctoral studies at the NIH, Bethesda, MD.
Advisors
-
Jim U. Jensen, JD, MBALawyerUnconfirmedA. Murat Croci, CPAAccountantUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.